Generic Pharmaceutical Savings Reach $217 Billion in 2012

Published Online: Wednesday, December 18, 2013
Follow Pharmacy_Times:

WASHINGTON, DC (December 18, 2013) — The Generic Pharmaceutical Association (GPhA) today released the fifth annual report, Generic Drug Savings in the U.S., showing that the use of generic medicines resulted in $217 billion in savings to the U.S. health care system in 2012 and $1.2 trillion over the last 10 years (2003-2012). For the first time, this year’s report features a special section on retail savings, confirming the savings that generic medicines deliver to millions of people.

“The generic pharmaceutical industry continues to generate unprecedented savings for the U.S. health system,” said Ralph G. Neas, President and CEO of the Generic Pharmaceutical Association (GPhA), which released the report. “As more Americans seek out affordable treatment options, generic medicines remain one of the few tried and true ways that patients, payers, the business community and others can find some relief from soaring health costs.”

For the first time, this report breaks out the savings for each payer type (i.e., out-of-pocket, insurers, Medicaid, other third-party payers) at the retail level. Retail sales represent approximately 76 percent of total savings from generics. In 2012 alone, savings for the retail markets totaled $171 billion. Interestingly, generics have saved out-of-pocket cash payers $78 billion over the past 10 years – these typically are the uninsured and poorer customers. All data were compiled by IMS Health on behalf of GPhA.

Select findings from the 2013 Generic Drug Savings Report:

Segment Savings from Generics
Retail market overall savings $931 Billion over 10 years
Commercial third-party payers (insurance companies, employee health plans) $552 billion over the past 10 years
Medicare Part D or other federal benefit enrollee savings $301 billion over 10 years
Seniors enrolled in Medicare Part D $189 billion since Part D program began in 2006
Medicaid beneficiaries who get prescriptions from retail outlets $96 billion over 10 years
Patients/Customers paying out-of-pocket (typically uninusred or underinsured) $78 billion over 10 years

“From policymakers to patients, any efforts to curtail health spending must capitalize on the savings from safe, affordable generic medicines. In a time when cutting costs is everyone’s priority, generics continue to put more treatments within reach for so many people,” said Neas. “Embracing policy that encourages access to generic medicines goes hand in hand with savings.”

Click here for the full report.
Related Articles
The FDA is seeking comments on 28 new and 15 revised recommendations providing product-specific guidance on the design of bioequivalence studies to support Abbreviated New Drug Applications (ANDAs).
Today, an expert panel at the 2015 Generic Pharmaceutical Association Annual Meeting, “FDA and Industry Perspectives on Quality Culture,” convened to discuss a shared commitment with industry to the highest standards of manufacturing quality and regulatory processes.
The Generic Pharmaceutical Association today announced the election of its 2015 Executive Committee and Board of Directors.
The Generic Pharmaceutical Association and its members applaud the significant progress made by the agency during Commissioner of Food and Drugs Dr. Margaret Hamburg’s six years leading the U.S. Food and Drug Administration. Throughout her tenure, Dr. Hamburg has been a tireless advocate for patient safety and a leader in efforts to assure that FDA decisions are guided by scientific principles.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times